Updated May 17, 2026 · 2142 articles
Insights
Research, news and field guides on institutional positioning. Powered by real SEC filings — 13F, 13D/G, Form 4.
What Is a 13D Filing? A Guide to Activist Investor Positions
Crossing 5% ownership of a public company triggers a Schedule 13D filing within 10 days. This explainer covers Item 4 intent, the 13D vs 13G distinction, amendment patterns, and how to read 13D filings on 13F Insight.
Sarah MitchellHow to Track Hedge Fund Portfolios Using 13F Data
13F filings are the only consistent window into hedge fund positioning. This explainer walks through the five-step workflow — picking funds, reading the baseline, tracking quarter-over-quarter changes, cross-referencing 13D/Form 4 — plus the gaps 13F cannot fill.
Sarah Mitchell13F Filing Season Guide: Deadlines and What to Watch
Four times a year, managers running over $100M in equity assets file Form 13F-HR with the SEC. This guide covers the 45-day rule, what's inside the filing, the 13F-HR vs 13F-NT distinction, and the reading order to use during filing season.
Sarah MitchellPortfolio Concentration: When Fewer 13F Holdings Mean More
Whether a top 13F holding represents real conviction depends on portfolio concentration. This explainer covers top-N concentration, holdings count, and how to read them against real examples from Pershing Square, Berkshire Hathaway, and Vanguard Group.
Sarah MitchellWhat Is AUM? The Three Numbers That Get Called the Same Thing
Assets under management means different things in different contexts: the firm's marketing number, the Form ADV regulatory number, and the 13F reported value are not the same. This explainer walks through what 13F AUM actually measures, and the five misreadings that get retail investors into trouble.
Sarah MitchellConsensus Holdings: Reading Where Active Funds Agree
Consensus holdings are stocks owned by many institutional investors at the same time, with real portfolio weight. This explainer walks through how to compute them, how to use the 13F Insight consensus tool, and the three traps retail readers fall into.
Sarah MitchellGates Foundation Trust Sells Last $3.7B of Microsoft in Q1
The Gates Foundation Trust's Q1 2026 13F-HR, filed May 15, shows zero Microsoft shares — ending a position that one quarter earlier was worth $3.7B and made up 10.5% of the portfolio. The foundation is now a four-name industrial stack led by Berkshire and Waste Management.
Alex RiveraDual-Class Shares and Insider Form 4 Filings
Many tech founders hold Class B shares with superior voting rights that don't appear in standard stock screeners. Understanding the dual-class structure helps investors read Form 4 Table II correctly and avoid underestimating an insider's real economic interest in their company.
Sarah MitchellWhat Is a Rule 10b5-1 Trading Plan?
A Rule 10b5-1 trading plan lets corporate insiders sell shares on a prearranged schedule without violating insider trading rules. Understanding how these plans work helps investors correctly interpret insider Form 4 filings and separate mechanical selling from discretionary conviction shifts.
Sarah MitchellRoku Founder Wood Sells $9.7M at $128-131
Roku founder and CEO Anthony Wood sold 75,000 Class A shares worth $9.7M on May 11, 2026 at prices from $128-131 per share under a prearranged 10b5-1 plan, while retaining 16.2 million Class B shares. FMR LLC holds 10.5% of the company.
Alex RiveraCrowdStrike CEO Sells at $560 Under 10b5-1 Plan
CrowdStrike CEO George Kurtz sold CRWD shares at $557-565 on May 14, 2026 under a Rule 10b5-1 prearranged plan — the latest in a multi-year pattern of programmatic selling at what are now post-outage recovery highs. Institutional investors Jennison Associates and Citadel remain large holders.
Alex RiveraAmeriprise Q1 2026: JPM -12%, MSFT -5%, Portfolio Contracts
Ameriprise Financial trimmed across its equity portfolio in Q1 2026, cutting JPMorgan by 12%, Microsoft by 5%, and Alphabet by 5% as holdings fell 2.8% to $373B. Broadcom (+6%) was the lone notable add.
Marcus ChenGoldman Sachs Q1 2026: +20% MSFT, +23% META, -16% TSLA
Goldman Sachs Group grew its 13F portfolio 6.4% to $735B in Q1 2026, adding aggressively to Microsoft (+20%) and Meta (+23%) while trimming Tesla by 16%. Nvidia remained the top holding at $38.47B.
Marcus ChenStarbucks Cuts 300 Jobs as Capital Group Holds $18B
Starbucks is cutting 300 corporate jobs under CEO Brian Niccol's turnaround plan. Despite the restructuring pain, Capital Group entities hold $18.43B in SBUX — ranking as the top two active institutional owners. Here's what the holder table reveals about conviction through the reset.
Alex RiveraNvidia Earnings Approach: 6,105 Holders, Goldman at $38B
As Nvidia approaches its Q1 FY2027 earnings report, analysts are resetting price targets. 13F Insight data shows 6,105 institutional holders with Goldman Sachs at $38.47B and Capital Research at $33.66B among the active-manager conviction plays.
Alex RiveraBerkshire Tripled Alphabet, Entered Delta in Q1 2026
Warren Buffett's Berkshire Hathaway disclosed a tripled stake in Alphabet and a fresh position in Delta Air Lines in its Q1 2026 13F. Here's what 13F Insight's institutional ownership data reveals about the broader conviction picture around GOOG and DAL.
Alex RiveraAlt Asset Manager 13Fs: Blackstone, KKR, Apollo, Brookfield
Blackstone, KKR & Co, Apollo Global Management, Brookfield Asset Management, plus Carlyle Group and Ares Management anchor US-traded alternative asset manager 13F positioning. Multi-year emerging private credit growth, fee-related earnings transition, plus emerging emerging retail alternative access drive distinctive institutional patterns.
Sarah MitchellMid-Cap Pharma 13Fs: Jazz, Vertex, Royalty Pharma, Halozyme
Jazz Pharmaceuticals, Royalty Pharma, Halozyme Therapeutics, Catalyst Pharmaceuticals, plus Organon and Viatris anchor US-traded mid-cap pharma 13F positioning. Multi-year emerging royalty financing dynamics, ENHANZE drug delivery, plus emerging emerging biosimilar plus generic dynamics drive distinctive institutional patterns.
Sarah MitchellGene Therapy 13Fs: Vertex-CRISPR, BioMarin, Sarepta, Beam, Editas
Vertex-CRISPR Therapeutics Casgevy, BioMarin Roctavian, Sarepta Elevidys, plus Beam Therapeutics, Editas Medicine, Intellia Therapeutics, and Verve Therapeutics anchor US-traded gene therapy 13F positioning. Multi-year emerging AAV gene therapy adoption, CRISPR gene editing, plus emerging emerging in-vivo gene editing drive distinctive institutional patterns.
Sarah MitchellSpecialty Biotech 13Fs: Sarepta, BioMarin, Alnylam, Ionis Inside
Sarepta Therapeutics, BioMarin Pharmaceutical, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, plus Vertex Pharmaceuticals and Insmed anchor US specialty biotech 13F positioning. Multi-year emerging rare disease economics, gene therapy adoption, plus emerging emerging RNAi plus antisense oligonucleotide platforms drive distinctive institutional patterns.
Sarah Mitchell